Letland - lettisk - Pārtikas un veterinārais dienests, Zemkopības ministrija

norbrook laboratories (ireland) limited, Īrija - borskābe,kalcija glikonāts,magnija hipofosfīts - šķīdums injekcijām - liellopi

Letland - lettisk - Zāļu valsts aģentūra

baxter latvia, sia, latvia - glikozes anhydricum, natrii chloridum, kalcija chloridum dihydricum, magnija chloridum hexahydricum, natrii hydrogenocarbonas, natrii (s)- lactatis risinājums - Šķīdums peritoneālai dialīzei - 38,6 mg/ml

Letland - lettisk - Zāļu valsts aģentūra

baxter latvia, sia, latvia - glikozes anhydricum, natrii chloridum, kalcija chloridum dihydricum, magnija chloridum hexahydricum, natrii hydrogenocarbonas, natrii (s)- lactatis risinājums - Šķīdums peritoneālai dialīzei - 13,6 mg/ml

Letland - lettisk - Zāļu valsts aģentūra

baxter latvia, sia, latvia - glikozes anhydricum, natrii chloridum, kalcija chloridum dihydricum, magnija chloridum hexahydricum, natrii hydrogenocarbonas, natrii (s)- lactatis risinājums - Šķīdums peritoneālai dialīzei - 22,7 mg/ml

Letland - lettisk - Zāļu valsts aģentūra

fresenius kabi polska sp.z o.o., poland - dekstrāns - Šķīdums infūzijām - 100 mg/ml

Letland - lettisk - Ecolab

ecolab deutschland gmbh -

Den Europæiske Union - lettisk - EMA (European Medicines Agency)

janssen-cilag international nv - darunavir - hiv infekcijas - pretvīrusu līdzekļi sistēmiskai lietošanai - prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). in deciding to initiate treatment with prezista co administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista 75 mg, 150 mg, and 600 mg tablets may be used to provide suitable dose regimens:for the treatment of hiv 1 infection in antiretroviral treatment (art) experienced adult patients, including those that have been highly pre treated. for the treatment of hiv 1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight. in deciding to initiate treatment with prezista co administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). prezista 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv 1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (art) naïve. art experienced with no darunavir resistance associated mutations (drv rams) and who have plasma hiv 1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 106/l. in deciding to initiate treatment with prezista in such art experienced patients, genotypic testing should guide the use of prezista.

Den Europæiske Union - lettisk - EMA (European Medicines Agency)

gilead sciences ireland uc - kobicistats - hiv infekcijas - pretvīrusu līdzekļi sistēmiskai lietošanai - tybost is indicated as a pharmacokinetic enhancer of atazanavir 300 mg once daily or darunavir 800 mg once daily as part of antiretroviral combination therapy in human immunodeficiency virus-1 (hiv-1) infected adults and adolescents aged 12 years and older:weighing at least 35 kg co‑administered with atazanavir orweighing at least 40 kg co‑administered with darunavir.

Den Europæiske Union - lettisk - EMA (European Medicines Agency)

janssen-cilag international nv - darunavir, cobicistat, emtricitabine, tenofovir alafenamide - hiv infekcijas - antivirals for systemic use, antivirals for treatment of hiv infections, combinations - symtuza indicēts cilvēka imūndeficīta vīrusa 1. tipa (hiv-1) infekcijas ārstēšanai pieaugušajiem un pusaudžiem (no 12 gadu vecuma un vecākiem ar ķermeņa svaru vismaz 40 kg). genotypic testing should guide the use of symtuza.

Letland - lettisk - Zāļu valsts aģentūra

baxter latvia, sia, latvia - glikozes monohydricum, kalcija chloridum, magnija chloridum, natrii chloridum, natrii lactas, natrii hydrogenocarbonas - Šķīdums peritoneālai dialīzei - 13,6 mg/ml